ReviewHuman vaccines & immunotherapeutics2026
Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mosunetuzumab is a bispecific antibody targeting CD20 x CD3 re-directing T cells to target and destroy CD20-positive B cells. T-cell-based therapies including bispecific antibodies have revolutionized B-cell NHL treatment. Mosunetuzumab is approved for follicular lymphoma with at least 2 prior lines of therapy. There are also NCCN recommendations for its use in diffuse large B-cell lymphoma and in combination with polatuzumab vedotin in relapsed/refractory mantle cell lymphoma with prior BTK inhibitor therapy. Published trials show low rates of severe CRS and support outpatient administration in appropriate settings. Utilizing a search of PubMed, conference abstracts, and clinicaltrials.gov between 2020 and 2026, prospective trial data as well as retrospective real-world evidence and ongoing studies were included for a more complete picture of available data. This review summarizes the molecular design, mechanism of action, clinical efficacy, and safety of mosunetuzumab, an agent representative of immunotherapeutic advancement in lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.